- Policy
- CKD completes acquiring 3 exclusive licensed items
- by Lee, Tak-Sun Aug 12, 2022 05:58am
- Chong Kun Dang completed the acquisition process for the three items that it signed exclusive sales agreements for with foreign pharmaceutical companies last year. All three items are known to have a prior history with Chong Kun Dang. According to industry sources on the 11th, Chong Kun Dang has been receiving insurance reimbursement for
- Policy
- Ceprotin, Takeda's rare dz, gives 11 yrs for reexamination
- by Lee, Hye-Kyung Aug 12, 2022 05:57am
- On the 2nd, Takeda's Ceprotin, which was first approved as a treatment for severe congenital protein C deficiency in Korea, was given an 11-year review period after marketing. Severe congenital protein C deficiency is a rare genetic disease that causes fatal defects in blood clot control due to a lack of protein C, a type of vitamin K-depende
- Policy
- Gov is reluctant to demand that infants be exempted from PE
- by Lee, Jeong-Hwan Aug 11, 2022 06:03am
- The government expressed reluctance to apply PE omission to rare drugs for infants, children, and adolescents. They say that it is a matter to be carefully considered in consideration of other drugs. On the 10th, the MOHW responded to a written question by Choi Hye-young of the Democratic Party of Korea, a member of the National Assembly's He
- Policy
- Reyvow, a migraine drug aimed at clinicians
- by Lee, Tak-Sun Aug 11, 2022 06:03am
- Ildong Pharmaceutical, which is seeking to introduce the new migraine drug Reyvow in Korea, has decided not to accept the upper limit offered by the Pharmaceutical Benefit Evaluation Committee of the Health Insurance Review and Assessment Service. The measure was decided in consultation with Lilly, who holds the global copyright of the drug,
- Policy
- "May bring 60M courses of Omicron-adapted COVID-19 vaccines"
- by Lee, Jeong-Hwan Aug 11, 2022 06:03am
- The disease control authorities announced that they may introduce the adapted, so-called ‘Omicron-specific COVID-19 vaccines’ as newly introduced amounts if the vaccines receive marketing authorization. In other words, if Moderna’s ‘Moderna Spikevax-2 inj.’ and Pfizer’s ‘Comirnaty-2 inj.’ that are being reviewed by the Ministry o
- Policy
- Will approval of brain function enhancers be revoked?
- by Lee, Hye-Kyung Aug 10, 2022 05:53am
- Whether acetyl-L-carnitine, which failed to verify its efficacy in its ‘secondary degenerative diseases caused by cerebrovascular disease’ indication during clinical reevaluations, will be able to maintain its marketing authorization status will be determined within September this year. The Ministry of Food and Drug Safety issued a Dear Hea
- Policy
- AZ seeks reimb of its triple inhaled therapy for COPD
- by Lee, Tak-Sun Aug 10, 2022 05:52am
- New triple drug inhaled therapies for COPD (Chronic Obstructive Pulmonary Disease) are working to receive insurance reimbursement in Korea. After GSK cut the first tape to reimbursement with its ‘Trelegy Elipta’ in June last year, AstraZeneca has also applied for the reimbursement of its ‘Breztri Aerosphere,’ which was approved in Novemb
- Policy
- When replacing Spinraza→Zolgensma, it should be injected
- by Lee, Hye-Kyung Aug 10, 2022 05:52am
- If SMA patients who were administering Biogen's Spinraza want to be replaced with Zolgensma, an ultra-high-priced one-shot treatment from Novartis Korea, they should have a minimum administration interval of 4 weeks. Regardless of whether or not benefit of Zolgensma is applied, replacement administration to other treatments after Zolgensma
- Policy
- Administration of Evusheld begins to prevent COVID-19
- by Kim, Jung-Ju Aug 9, 2022 05:57am
- From today (8th), the quarantine authorities will administer Evusheld, an antibody injection for prevention, for severely immunocompromised patients. The COVID-19 Vaccination Response Promotion Team (Director Baek Kyung-ran) announced today (the 8th) that it will start taking Evuseld to prevent COVID-19 among immunocompromised people. Evuseld
- Policy
- Oxiracetam’s next...ordeal of brain function enhancers
- by Lee, Tak-Sun Aug 9, 2022 05:56am
- It’s a time of ordeal for brain function enhancers. In addition to choline alfoscerate, whose scope of use has been reduced through reimbursement reevaluations, acetyl-L-carnitine failed to demonstrate its efficacy during clinical reevaluations. As a result, acetyl-L-carnitine is expected to completely disappear from the prescrip
